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ABSTRACT A critical appraisal and clinical application of Devinsky O, Cross H, Laux L, et al. Trial of Cannabidiol for Drug-
Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. 
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Clinical Context 
Aiden Williams (pseudonym), a 12 year old boy presented to neurology clinic for follow up of Dravet syndrome. He 
was diagnosed at 5 months old following a febrile generalized tonic clonic (GTC) seizure. He was found to have 
loss-of-function SCN1A mutations associated with Dravet syndrome. At that time he was placed on valproate. Due 
to the continued presence of four or more convulsive seizures a month, the patient’s regimen was later modified. 
Currently, his antiepileptic drug (AED) regimen consists of valproate, clobazam, stiripentol and a ketogenic diet. His 
mother is concerned about continued episodes of about seven GTC seizures a month despite avoidance of triggers. 
His mother read an online blog about the new FDA approval of cannabidiol (CBD) as an adjunctive agent in 
treatment of drug-resistant seizures of Dravet syndrome. She would like to consider  it as an option. She asked the 
team if CBD treatment could improve her son’s seizure control. As a team, we felt it was appropriate to consider 
the addition of CBD. 
Clinical Question 
Is adjunctive cannabidiol a beneficial addition to current antiepileptic  regimen in the treatment of children with drug resistant 
Dravet syndrome? 
Research Article 
Devinsky O, Cross H, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 
2017;376(21):2011-2020. doi: 10.1056/NEJMoa1611618 
Related Literature 
The patient’s mother found information about CBD on an online blog that focused on its current research and therapeutic 
applications.1 A PubMed search was conducted using the terms “Dravet Syndrome[title] and cannabidiol[title]” as well as 
“Cannabidiol Dravet.” References were also reviewed in articles on cannabidiol use in Dravet syndrome on UpToDate. This searc h 
resulted in sixty nine articles, with eleven specifically focusing on Dravet syndrome and cannabidiol therapy: three clinical  trials with 
human subjects2,3,4, one clinical trial with a mouse model5, five commentaries6–10, one review11, and one case report.12 The review 
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article11 and commentaries6–8,10 focused on one of the human clinical trials.3 In addition, another clinical trial considered use of THC 
combined with CBD in treatment of Dravet syndrome.2 The final clinical trial with human subjects is newly published.4 The case 
report focused on successful use of cannabidiol in one patient.12 Therefore together these articles represent the collective 
knowledge on this subject. Of note, two clinical trials with human subjects were conducted by Devinsky and his team.  
The case report by Bravo and Izquierdo focused on a 19 year old female with Dravet syndrome.12 Administration of CBD as adjuvant 
therapy significantly reduced her number of daily seizures. However, due to the focus on one patient, the report lacks reliability and 
cannot be considered strong enough for clinical use. 
The McCoy et. al 2018 clinical trial paper was an open-label interventional study involving 20 children ages 1-18 who had established 
drug resistant Dravet syndrome.2 The participants were randomized to receive 2 to 16 mg/kg/day of CBD and 0.04 to 0.32 
mg/kg/day of THC. The primary objective was to establish dosing and tolerability of treatment. Inclusion criteria included: c onfirmed 
SCN1A mutation, expected EEG findings, stable AED regimen for four weeks, frequent motor seizures, and ketogenic diet or 
vasovagal stimulation for 3 months. Nineteen patients completed the intervention, with eighteen reporting adverse events alth ough 
most resolved by week eight of twenty. No patient was able to tolerate the 16 mg/kg/day dose of CBD, but most participants were 
titrated to a dose they could tolerate. Overall, a statistically significant reduction in motor seizures was observed. The main 
limitations of this study are the small sample size and lack of control group.  
The Devinsky et. al 2018 paper was a placebo controlled, double blinded, randomized trial of 34 patients. 4 The aim of the study was 
to determine the pharmacokinetics and safety of a purified CBD formulation in children with Dravet syndrome in preparation for a 
larger randomized controlled trial. The study consisted of 3 experimental groups differing in dosage of CBD (5, 10, or 20 mg/ kg/d) 
and 1 control placebo group. Patients given any of the three doses showed increased CBD metabolite levels and adverse events 
compared to placebo, but overall tolerated CBD treatment. Although this study is one of the most recent in this field, the pa per had 
a limited sample size and the primary objective related to the pharmacokinetics and safety of CBD rather than its efficacy as an 
adjuvant therapy for drug resistant Dravet syndrome patients. 
The Devinsky et. al 2017 paper was a placebo controlled, double blinded, randomized trial of 120 patients with  drug resistant Dravet 
syndrome.3 The objective of the study was assessing the role of adjuvant CBD in reduction of convulsive seizure frequency. Patients 
who received CBD had greater reduction in convulsive seizure frequency when c ompared to patients who were given placebo, 
although the CBD group experienced higher rates of adverse events. The study methodology of this paper was superior to 
alternative papers due to the greater number of study participants combined with randomizatio n, double blinding, and placebo 
group comparison. Additionally, a Nature review article on the use of CBD in treating Dravet syndrome found this therapeutic trial to 
be significantly informative in the field.11 For these reasons, I chose this paper for critical appraisal to evaluate whether adjunctive 
CBD therapy will improve seizure control of our patient. 
Critical Appraisal 
This double blinded, randomized, and placebo controlled multicenter study meets Category A and level 1 study  quality with the 
SORT criteria. The primary outcome of the study was change in convulsive seizure frequency over a 14 week treatment period 
compared to a 4 week baseline.  Secondary end-point measurements included: improvement or worsening in quality of l ife, 
reduction in total seizure and subtype seizure frequencies, sleep disruption, age -related behavior, number of hospitalizations due to 
epilepsy, number of patients with emergence of seizure types that did not present during the baseline period, and use  of rescue 
medication. The team also looked at CBD safety profile by measuring number, type, and severity of adverse events. Thus the ar ticle 
considered both disease-oriented and patient-oriented outcomes. 
This study recruited 120 participants aged 2-18 years old from 23 healthcare centers in the United States and Europe who were 
randomized into placebo (control) and cannabidiol (experimental) groups. Inclusion criteria included: an established diagnosi s of 
Dravet syndrome, taking one or more AED’s, and having four or more convulsive seizures during the 28-day baseline period. 
Exclusion criteria was not defined. The patients in the study were on an average of three AED’s with continued seizure activi ty. Both 
the number and type of drugs used to manage Dravet syndrome in a setting of continued drug-resistant epilepsy match our patient’s 
profile. 
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All patients were first observed for a 4 week baseline period prior to initiation of 14 weeks of therapy followed by an optio n to enroll 
in an open label extension study or continue with 10 day taper and 4 week safety follow up period. Both groups continued to receive 
their standard AED regimen. In addition, the experimental group (N = 61) received a 20 mg/kg/d solution of CBD twice daily wh ile 
the control group (N = 59) received a placebo solution infusion of the same quantity and frequency. Experimental and control groups 
were reasonably similar apart from unequal distribution of sex with 57% of the experimental group male versus 46% of the cont rol 
group. At the end of treatment, nine withdrew from the experimental group, eight due to adverse events and one due to non -
adherence, for a total of 52 completing the trial. Adverse events included: diarrhea, vomiting, fatigue, pyrexia, somnolence,  and 
abnormal liver function tests. In contrast, three withdrew from the control group due to adverse events and a total of 56 completed 
the treatment period. Therefore a total of 90% completed the full trial, 85% of the experimental group and 95% of the control  group. 
Analysis of both groups revealed a significant reduction in convulsive seizure frequency in the experimental group (38.9%) compared 
to control (13.3%) with p = 0.01 and NNT = 4. Thus, there was a large effect size difference supporting the use of CBD in tre ating 
convulsive seizures. However, there was no significant change in frequency of non-convulsive seizures between groups which may 
either be due to inability of caregivers to recognize the episodes or CBD’s mechanism of action. All other secondary outcomes  were 
also insignificantly changed between groups. Of note, adverse events occurred significantly more in the experimental group and with  
greater severity (16% in experimental versus 5% in control). One limitation of the study was that the adverse events may have  
unblinded patients and caregivers to which treatment group they were randomly assigned to. A post hoc analysis by investigators 
addressed this pitfall and found no relationship between somnolence, the most common adverse event, and the treatment effect.   
Another limitation of the study was funding by GW Pharmaceuticals, a company that focuses on cannabinoid drugs and which 
provided the CBD used by investigators. Employees of the funding agency were involved with study design, data analysis, and 
compilation of the article which increases risk of sponsorship bias. 
Overall despite minor flaws, this study showed CBD caused a statistically significant reduction in convulsive seizure frequen cy for 
Dravet syndrome patients with drug-resistance. CBD can feasibly be added to current AED regimens with close monitoring for 
adverse events. 
Clinical Application 
Ultimately, there is ongoing research about the use of CBD in epilepsy management. In June 2018 based on this 
current body of research, the FDA approved cannabidiol oral solution for treatment of seizures associated with 
Dravet syndrome and Lennox-Gestaut syndrome.13 This opens up a new therapeutic option for physicians and 
patients thus necessitating a discussion of CBD use based on scientific evidence of benefits and risks.  
Based on this study, CBD significantly decreased frequency of convulsive seizures. This conclusion was relevant to 
Aiden, who suffered from GTC seizures. It is important to ascertain from the patient or caregiver what seizure type 
the patient suffers from when considering adjunctive CBD. Additionally, during treatment close monitoring is 
required due to higher incidence and severity of adverse events. Furthermore, caregivers require education on 
administration of CBD along with the tapering process if treatment is discontinued. Aiden and his mother as his 
caregiver were able to decide in favor of adjunctive CBD therapy after discussion of the benefits versus risks of 
therapy. When asked what the patient sought with treatment, he identified control of his convulsive seizures as his 
primary goal and we as his care team felt the CBD could help achieve this goal. In the end, Aiden, his mother, and 
us, his care team, were all hopeful CBD would improve seizure control. 
Learning points: 
1. Cannabidiol benefits Dravet syndrome patients with drug-resistant convulsive seizures by reducing seizure 
frequency. 
2. Cannabidiol comes with risk of adverse events, primarily somnolence, which may limit tolerability of 
treatment. 
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3. Management of children with epileptic syndromes requires coordination between their caregivers, who may 
derive medical information from online sources, and physicians. 
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